hairy cell leukemia: a retrospective study on 11 patients in the western of iran.

background: hairy cell leukemia (hcl) is a chronic b-cell lymphoid leukemia characterized by pancytopenia, splenomegaly, myelofibrosis and the presence in peripheral blood, bone marrow and spleen of atypical lymphoid cells with a hairy aspect. the study aims to evaluate a group of patients with hairy cell leukemia, hospitalized in the clinic of hematology and oncology, kermanshah, iran, on a period of 15 years and affect of between cladribine therapy and ifn therapy on the patients with hcl. methods: this is a retrospective analysis of 11 patients in the clinic of hematology and oncology, kermanshah, iran, between 2004 and 2013. clinical features at diagnosis, differential count (platelet, hb and wbc) types of therapy, survival rate and braf mutation have been monitored. as a result, cladribine therapy is the best treatment option for patients. results: the mean age of patients was 50 years with 100% of men. approximately 45% of them had splenomegaly at diagnosis. 100% of patients had pancytopenia at diagnosis.9% of patients had mutation of braf v600e. before of treatment, there were fatigue, weight loss, vomiting, fever, night sweat and itching in all of the patients. conclusion: there is presence of hairy cells in peripheral blood and bone marrow and was associated with pancytopenia, splenomegaly, myelofibrosis in hcl patients. also, cladribine therapy is best option for treatment of patients and it is better than ifn.